SEC Form SC 13D/A filed by Centogene N.V. (Amendment)

SEC Form SC 13D/A filed by Centogene N.V. (Amendment)

Recent Analyst Ratings for
$CNTG

$CNTG
SEC Filings

$CNTG
Analyst Ratings

$CNTG
Market Insights

$CNTG
Press Releases

$CNTG
Financials

$CNTG
Leadership Updates

$CNTG
Large Ownership Changes

Chat with this insight

SEC Form 6-K filed by Centogene N.V.

SEC Form 6-K filed by Centogene N.V.

SEC Form 6-K filed by Centogene N.V.

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Credit Suisse resumed coverage on Centogene with a new price target

Credit Suisse reiterated coverage on Centogene with a new price target

Live Market Insights

Centogene shares are trading higher after the company signed a Memorandum of Understanding with C-Path for collaboration in lysosomal disease research and drug development.

Centogene And C-Path Sign MOU For Collaboration In Lysosomal Disease Research And Drug Development

Centogene shares are trading higher after the company reported a year-over-year increase in FY23 EPS results.

Fastest customizable press release news feed in the world

Live finance-specific insights

Live Leadership Updates

This live feed shows all institutional transactions in real time.

CENTOGENE Data on Novel Genetic Risk Factor for Parkinson's Disease in The Lancet Neurology

CENTOGENE Receives Delisting Notice From Nasdaq

CENTOGENE Publication in Brain Journal Reveals 15% of Parkinson's Disease Cases Are Linked to Genetic Factors

CENTOGENE Reports Fourth Quarter and Full Year 2021 Financial Results

CENTOGENE to Announce Fourth Quarter and Fiscal Year 2021 Financial Results on March 30, 2022

CENTOGENE Reports Third Quarter 2021 Financial Results

CENTOGENE Reports First Half 2023 Financial Results

CENTOGENE Announces Approval of All Resolutions Tabled at 2023 Annual General Meeting

CENTOGENE Reports Full Year 2022 Financial Results

3/11/22 4:44:52 PM ET

$CNTG

Medical Specialities

Health Care

Get the next $CNTG alert in real time by email

SC 13D/A 1 d250110dsc13da.htm SC 13D/A SC 13D/A

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D/A

Under the Securities Exchange Act of 1934

(Amendment No. 2)*

Centogene N.V.

(Name of Issuer)

Common Shares, €0.12 par value per share

(Title of Class of Securities)

N1976T109

(CUSIP Number)

Stefan Fischer

TVM Capital

Ottostrasse 4

80333 Munich, Germany

(49) 89998992-48

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

January 31, 2022

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Section 240.13d-7 for other parties to whom copies are to be sent.

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. N1976T109


1.		Names of Reporting Persons. TVM Life Science Innovation I L.P.
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
3.		SEC Use Only
4.		Source of Funds (See Instructions) WC
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Quebec, Canada

CUSIP No. N1976T109


1.		Names of Reporting Persons. TVM Life Science Innovation I (GP) Limited
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
3.		SEC Use Only
4.		Source of Funds (See Instructions) AF
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Jersey

CUSIP No. N1976T109


1.		Names of Reporting Persons. TVM Life Science Innovation II SCSp
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
3.		SEC Use Only
4.		Source of Funds (See Instructions) WC
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Luxembourg

CUSIP No. N1976T109


1.		Names of Reporting Persons. TVM Life Science Innovation II (GP) S.a r.l.
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
3.		SEC Use Only
4.		Source of Funds (See Instructions) AF
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Luxembourg

CUSIP No. N1976T109


1.		Names of Reporting Persons. Hubert Birner
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
3.		SEC Use Only
4.		Source of Funds (See Instructions) AF
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Germany

CUSIP No. N1976T109


1.		Names of Reporting Persons. Stefan Fischer
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
3.		SEC Use Only
4.		Source of Funds (See Instructions) AF
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Germany

CUSIP No. N1976T109


1.		Names of Reporting Persons. Luc Marengere
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
3.		SEC Use Only
4.		Source of Funds (See Instructions) AF
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Canada

CUSIP No. N1976T109


1.		Names of Reporting Persons. Reshentha Beeby
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
3.		SEC Use Only
4.		Source of Funds (See Instructions) AF
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Canada

CUSIP No. N1976T109


1.		Names of Reporting Persons. Gary Leatt
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
3.		SEC Use Only
4.		Source of Funds (See Instructions) AF
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Canada

CUSIP No. N1976T109


1.		Names of Reporting Persons. Monica Morsch
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
3.		SEC Use Only
4.		Source of Funds (See Instructions) AF
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Canada

CUSIP No. N1976T109


1.		Names of Reporting Persons. Jens Hoellermann
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
3.		SEC Use Only
4.		Source of Funds (See Instructions) AF
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Canada

CUSIP No. N1976T109


1.		Names of Reporting Persons. Ganash Lokanathen
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
3.		SEC Use Only
4.		Source of Funds (See Instructions) AF
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Canada

Explanatory Note

This Amendment No. 2 (this “Amendment) amends and supplements the Schedule 13D filed with the Securities and Exchange Commission on January 14, 2020 by the Reporting Persons (as amended from time to time, the “Schedule 13D”), relating to their beneficial ownership of shares of Common Stock of Centogene N.V. (the “Issuer”). Except to the extent set forth in this Amendment, all material information disclosed in the Schedule 13D remains unchanged. Capitalized terms used but not defined in this Amendment have the respective meanings set forth in the Schedule 13D.

Item 3.

Source and Amount of Funds or Other Consideration

Item 3 of the Schedule 13D is hereby amended and supplemented as follows:

TVM II purchased the securities set forth in Item 5 using funds from working capital.

Item 5.

Interest in Securities of the Issuer

Item 5 of the Schedule 13D is hereby amended and supplemented as follows:

(a)-(b) The information set forth in rows 7 through 13 of the cover pages to this Schedule 13D is incorporated by reference. The percentage set forth in row 13 is based on 27,066,224 outstanding shares of Common Stock, as reported by the Issuer to the Reporting Persons, and includes the Warrants set forth in Item 5(c) below.

(c) On January 31, 2022 TVM II acquired 1,493,029 shares of Common Stock and warrants to acquire 447,909 shares of Common Stock (“Warrants”) from the Issuer at a purchase price of $3.73 per share in the Issuer’s private placement financing. The Warrants are exercisable at an exercise price of $7.72 per share at an exercise price of $7.72 per share and expire December 31, 2026.

Item 6.

Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

Item 6 of the Schedule 13D is hereby amended and supplemented as follows:

The information set forth in Item 5(c) above is incorporated by reference into this Item 6.

The securities set forth in Item 5(c) were acquired pursuant to a Securities Purchase Agreement, a copy of which is filed as Exhibit 4 to this Schedule 13D and is incorporated by reference into this Item 6.

Item 7.

Material to be Filed as Exhibits

Item 7 of the Schedule 13D is hereby amended and supplemented as follows:

Exhibit 4 Securities Purchase Agreement, dated January 31, 2022, by and among Centogene N.V. and the Investors identified on Schedule 1 attached thereto (incorporated by reference to Exhibit 99.4 to the Issuer’s Form 6-K furnished with the SEC on February 1, 2022) (the Issuer has omitted portions of this exhibit pursuant to Item 601(b)(10)(iv) of Regulation S-K on the basis that the Company customarily and actually treats that information as private or confidential and the omitted information is not material)

Exhibit 5 Warrant Agreement, dated January 31, 2022, by and among Centogene N.V. and the Investors identified on Schedule 1 attached thereto (incorporated by reference to Exhibit 99.5 to the Issuer’s Form 6-K furnished with the SEC on February 1, 2022)

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: March 11, 2022

TVM LIFE SCIENCE INNOVATION I L.P.

By: TVM LIFE SCIENCE INNOVATION I (GP) LIMITED, its general partner


By:		/s/ Reshentha Beeby
Name:		Reshentha Beeby
Title:		Director

TVM LIFE SCIENCE INNOVATION I (GP) LIMITED


By:		/s/ Reshentha Beeby
Name:		Reshentha Beeby
Title:		Director

TVM LIFE SCIENCE INNOVATION II SCSP

By: TVM LIFE SCIENCE INNOVATION II (GP) S.A R.L., its general partner


By:		/s/ Monica Morsch
Name:		Monica Morsch
Title:		Class B Manager

By:		/s/ Ganash Lokanathen
Name:		Ganash Lokanathen
Title:		Class A Manager

TVM LIFE SCIENCE INNOVATION II (GP) S.A R.L.


By:		/s/ Monica Morsch
Name:		Monica Morsch
Title:		Class B Manager

By:		/s/ Ganash Lokanathen
Name:		Ganash Lokanathen
Title:		Class A Manager

/s/ Hubert Birner

Hubert Birner

/s/ Stefan Fischer

Stefan Fischer

/s/ Luc Marengere

Luc Marengere

/s/ Reshentha Beeby

Reshentha Beeby

/s/ Gary Leatt

Gary Leatt

/s/ Monica Mosch

Monica Mosch

/s/ Jens Hoellermann

Jens Hoellermann

/s/ Ganash Lokanathen

Ganash Lokanathen

Get the next $CNTG alert in real time by email

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person

With

Sole Voting Power

0

Shared Voting Power

1.632.606

Sole Dispositive Power

0

Shared Dispositive Power

1.632.606